A Real-World Observational Analysis Comparing the Effectiveness and Safety of Treatment with Apixaban Versus Other Oral Anticoagulants Among Elderly Non-valvular Atrial Fibrillation Patients.

Trial Profile

A Real-World Observational Analysis Comparing the Effectiveness and Safety of Treatment with Apixaban Versus Other Oral Anticoagulants Among Elderly Non-valvular Atrial Fibrillation Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban; Warfarin
  • Indications Embolism; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2017 Results (n=57025) presented at the 90th Annual Scientific Sessions of the American Heart Association.
    • 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association
    • 10 Nov 2017 According to Bristol-Myers Squibb media release, data will be presented at 2017 American Heart Association (AHA) Scientific Sessions.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top